Echo Therapeutics Announces Withdrawal of Proposed Follow-On Offering

Nov 29, 2012, 07:30 ET from Echo Therapeutics, Inc.

PHILADELPHIA, Nov. 29, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it has withdrawn the previously announced proposed underwritten public offering of its common stock due to market conditions.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

For More Information: 
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications  
(215) 717-4104   
colimpio@echotx.com                                         

Connect With Us: 
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx 

 

SOURCE Echo Therapeutics, Inc.



RELATED LINKS

http://www.echotx.com